Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - sevelamer carbonate -

United States - English - NLM (National Library of Medicine)

sanofi-aventis u.s. llc - zolpidem tartrate (unii: wy6w63843k) (zolpidem - unii:7k383oqi23) - zolpidem tartrate 5 mg - ambien (zolpidem tartrate) is indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. ambien has been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see clinical studies (14)] . the clinical trials performed in support of efficacy were 4–5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. ambien is contraindicated in patients - who have experienced complex sleep behaviors after taking ambien [see warnings and precautions (5.1)] . - with known hypersensitivity to zolpidem. observed reactions include anaphylaxis and angioedema [see warnings and precautions (5.4)] . risk summary neonates born to mothers using zolpidem late in the third trimester of pregnancy have been reported to experience symptoms of respiratory depression and sedation [see clinical considerations and data] . published data on the use of zolpidem during pregnancy have not reported a clear association with

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - lixisenatide -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - teriflunomide -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium -

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - enoxaparin sodium, quantity: 80 mg - injection, solution - excipient ingredients: water for injections; nitrogen - prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery. prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness. prevention of thrombosis in extra-corporeal circulation during haemodialysis. treatment of established deep vein thrombosis. treatment of unstable angina and non-q-wave myocardial infarction, administered concurrently with aspirin. treatment of acute st-segment elevation myocardial infarction (stemi) as an adjunctive to thrombolytic treatment, including patients to be managed medically or with subsequent percutaneous coronary intervention (pci).

Israel - English - Ministry of Health

sanofi israel ltd - dupilumab - solution for injection - dupilumab 150 mg/ml - dupilumab - atopic dermatitisdupixent is indicated for the treatment of treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (ad) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. dupixent can be used with or without topical corticosteroids.asthmadupixent is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma.limitation of usedupixent is not indicated for the relief of acute bronchospasm or status asthmaticus. chronic rhinosinusitis with nasal polyposisdupixent 300mg is indicated as an add-on maintenance treatment in adult patients with inadequately controlled chronic rhinosinusitis with nasal polyposis (crswnp).eosinophilic esophagitisdupixent is indicated for the treatment of adult and pediatric patients aged 12 years and older, weighing at least 40 kg, with eosinophilic esophagitis (eoe).prurigo nodularisdupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy.

Israel - English - Ministry of Health

sanofi israel ltd - dupilumab - solution for injection - dupilumab 175 mg/ml - dupilumab - atopic dermatitis dupixent is indicated for the treatment of treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe atopic dermatitis (ad) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. dupixent can be used with or without topical corticosteroids. asthma dupixent is indicated as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. limitation of use: dupixent is not indicated for the relief of acute bronchospasm or status asthmaticus.

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi - aventis groupe - insulina glargina - insulina glargina....100 ui/ml / lixisenatida....50 mcg/ml

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

sanofi - aventis groupe - irbesartan - irbesartan....300 mg / hidroclorotiazida....25 mg